Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT) | BIOLOGICAL | - |
Inclusion Criteria: * Male and female volunteers infants, aged 2 to 6 months * Clinically healthy, (i.e. the physician would have no reservations vaccinating with a meningococcal C vaccine outside the scope of a clinical trial) * Parent(s)/legal guardian understands the study and has provided writt...
The Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine is an investigational vaccine developed by Pfizer for the prevention of meningitis caused by group C meningococcal bacteria. It is designed for use in healthy infants and is given alongside routine childhood immunizations. It is also known by the abbreviation GCMP-TT.
It is used for immunization against meningitis caused by group C meningococcal bacteria. The vaccine is intended for healthy infants from two months of age, with the goal of protecting them against meningococcal disease. It is studied in combination with other routine infant vaccines.
Pfizer, Inc. is the developer of the Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine. Pfizer trades on the New York Stock Exchange under the ticker PFE. The company sponsored the clinical trial evaluating this vaccine candidate.
The Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine has been studied in Phase 3 clinical development. It is an investigational vaccine and is not described as approved. The single Phase 3 trial has been completed, and no trials are currently active.
The vaccine was evaluated in one completed Phase 3 trial, NCT00161928, titled Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants. The trial enrolled 330 healthy infants in Austria and Germany and was randomized.
Yes. GCMP-TT is the abbreviated name for the Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine. Both names refer to the same Pfizer vaccine candidate studied for prevention of group C meningococcal meningitis in healthy infants.